Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

OSLO, Dec 5 (Reuters) - Danish Novo Nordisk said

on Monday it has filed for the European Union and the U.S.

approval of semaglutide to treat adults with type 2 diabetes.

Read more